Twist Bioscience reported its fiscal fourth quarter and full year results on November 12, in a release filed with the SEC that the previous edition did not cover. Revenue for fiscal 2026, which ended September 30, rose to a record 459.4 million dollars, up 22 percent from 376.6 million dollars in fiscal 2025. Fourth quarter revenue was 126.6 million dollars, up about 28 percent from 99.0 million dollars a year earlier, and the company notes this was its fifteenth consecutive quarter of sequential growth.
Growth came from both halves of the business. DNA synthesis and protein solutions revenue grew 31.7 percent to 221.9 million dollars, while next generation sequencing applications revenue grew 14.1 percent to 237.5 million dollars. Gross margin widened to 52.4 percent for the year, up 1.7 points from 50.7 percent, and chief executive Emily Leproust said the fourth quarter delivered positive adjusted EBITDA.
For fiscal 2027 the company guided revenue to 550 million to 560 million dollars, growth of 21 percent at the midpoint, with first quarter revenue of 130 million to 132 million dollars, growth of 26 percent at the midpoint. Management framed the outlook around artificial intelligence expanding what scientists can design and personalised medicine increasing demand for unique molecules, both of which favour a custom synthesis platform.
Twist is a supplier rather than a drug developer, so its print carries no approval or trial risk. What it does carry is a demand signal: sustained growth above 20 percent, with margin expansion, says laboratory and discovery spending by its pharmaceutical and biotechnology customers is still expanding into 2027.